VERTEX PHARMACEUTIC (VX1 HM) stock market data APIs
€356.4356
-10.59(-3%)
as of October 17, 2025
Try our APIs with
free plan!
VERTEX PHARMACEUTIC Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for VX1.HM.
Prev. Close
356.4356
Open
345.8471
High
356.4356
Low
345.8471
52 wk Range
313.05-483.05
Market Cap
46 841 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get VERTEX PHARMACEUTIC data using free add-ons & libraries
Get VERTEX PHARMACEUTIC Fundamental Data
VERTEX PHARMACEUTIC Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
VERTEX PHARMACEUTIC News
New
A Closer Look at Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Stability
Vertex Pharmaceuticals (VRTX) shares have been fairly steady recently, as investors digest the company’s financial performance over the past month. The stock is up 8% since early May. This reflects ...
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
Vertex Pharmaceuticals (VRTX) ended the recent trading session at $416.81, demonstrating a +2.01% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's dail...
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal developm...
Vertex Pharmaceuticals: Commercial Pipeline Is Stronger Than What The Market Thinks
This article first appeared on GuruFocus. If you are going to make your first investment in a bio-tech company, might as well do it in a strong one like Vertex Pharmaceuticals (NASDAQ:VRTX). Shares h...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
